Clinical Trial Search

Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of R-warfarin and S-warfarin — 19200; 18900; 33000; 32900 nanograms times hours per milliliter

Primary: Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) — 1900; 2180 picomole*hour per liter (pmol*hr/L)

Primary: High Frequency Heart Rate Variability — 6.31; 5.48 ln(msec)

Primary: Intubation Success Rate — 512; 531 participants

Primary: Change of Dry Eye Symptoms — 40.1; 46.2; 39.7; 15.9 units on a scale

Primary: Pharmacokinetics: Maximum Observed Concentration (Cmax) — 84.5; 63.0; 58.1; 61.3 nanograms/milliliter (ng/mL)

Primary: Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY2963016 and US-Approved Lantus — 1720; 1900 picomoles*hour/liter (pmol*h/L)

Primary: % Weight Change From Baseline — 5.5; 0.9 % weight change

Primary: Maximum Insulin Concentration (Cmax) - First Phase Response — 233; 689; 74.3; 401 picomole per liter (pmol/L) — p=<0.001

Primary: Pharmacodynamics: Duration of Action of LY2963016 and Lantus — 37.13; 40.00 hours (hr)

Primary: Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 and Lantus — 1810; 1980 picomoles*hour/Liter (pmol*h/L)

Primary: Exercise Endurance — 18.1; 14.5; 11.5 minutes — p=0.015

Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Digoxin — 16.8; NA; NA; 16.1 nanograms times hours/milliliter

Primary: Pharmacokinetics: Area Under the Serum LY2963016 or Lantus Concentration-Time Curve (AUC) From Zero to Infinity [AUC(0-∞)] — 2330; 4470; 2390; 4310 picomoles*hour per…

Primary: Total Airway Resistance Increase — 47; 22.9 ln(mg/mL)